Logo

Mochida Receives Marketing Authorization for Teriparatide Biosimilar in Japan

Share this

Mochida Receives Marketing Authorization for Teriparatide Biosimilar in Japan

Shots:

  • Teriparatide biosimilar is the first product developed under Mochida and Gedeon Richter license agreement and is expected to improve the QoL while reducing the financial burden of patients with osteoporosis
  • Teriparatide BS Injection Kit 600μg is a novel biosimilar approved in Japan targeted for osteoporosis with a recommended dose of 20 μg SC once a day that enhances bone formation and improves bone structure
  • It is a disposable kit enabled with a delivery device and can also be self-injected with the announcement of its expected launch at the National Health Insurance Price Listing

Click here to­ read full press release/ article | Ref: Mochida | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions